Du Changzheng, male, associate professor in South University of Science and Technology Medical School. He has been engaged in gastrointestinal oncology for more than ten years and is good at the multidisciplinary treatment and surgery of gastrointestinal tumor， especially the colorectal cancer. He has abundant clinical experience on the anal-sparing surgery for low rectal cancer, as well as the individual treatment after neoadjuvant chemoradiotherapy. He also has rich experience in basic research, including tumor molecular biology and epigenetics, with special interests on clinical translation of basic research. He has published more than 20 papers in first-class journals such as Cell Report and Cancer Letters. He owns an invention patent and a utility patent.
Prof. Du has been working as a first-line doctor in surgical treatment of digestive malignant tumor for more than 10 years, with abundant clinical experience. He delivered the first clinical trial of non-surgery treatment for rectal cancer in China, which was displayed at the 2018 ASCO meeting and included in Journal of Clinical Oncology. Prof. Du uses basic research to solve clinical problems, focusing on translating lab work into clinic use. The research fields including cancer molecular biology, signal pathway/ therapeutic targets, and epigenetics. Prof. Du has published more than 20 papers during the past decade in the first-class SCI journals, such as Cell Report, Cancer Letters and others.
Recent 5 years：
1. Du, C., S. W. Li, S. X. Singh, K. Roso, M. A. Sun, C. J. Pirozzi, R. Yang, J. L. Li and Y. He (2021). "Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization." Mol Cancer Res.
2. Han, Z., M. Li, J. Chen, D. Ji, T. Zhan, Y. Peng, W. Xue, Y. Li, Y. Cai, Y. Sun, Q. Wu, C. Du and J. Gu (2021). "Surgery may not benefit patients with locally advanced rectal cancer who achieved clinical complete response following neoadjuvant chemoradiotherapy." Asian J Surg.
3. Du, C., Y. Peng, Y. He, G. Chen and H. Chen (2021). "Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer." Int J Biol Markers 36(1): 47-53.
4. Dan, C., H. Pei, B. Zhang, X. Zheng, D. Ran and C. Du (2021). "Fanconi anemia pathway and its relationship with cancer." Genome Instability & Disease 2(3): 175-183.
5. Du, C. Z., Z. H. Fan, Y. F. Yang, P. Yuan and J. Gu (2019). "Value of intra-operative Doppler sonographic measurements in predicting post-operative anastomotic leakage in rectal cancer: a prospective pilot study." Chin Med J (Engl) 132(18): 2168-2176.
6. Du, C., L. J. Hansen, S. X. Singh, F. Wang, R. Sun, C. J. Moure, K. Roso, P. K. Greer, H. Yan and Y. He (2019). "A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis." Cell Rep 28(12): 3199-3211 e3195.
7. Cao, L. L., C. Du, H. Liu, L. Pei, L. Qin, M. Jia and H. Wang (2018). "Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma." Int J Biol Markers: 1724600818764069.
8. Tang, M., X. Lu, C. Zhang, C. Du, L. Cao, T. Hou, Z. Li, B. Tu, Z. Cao, Y. Li, Y. Chen, L. Jiang, H. Wang, L. Wang, B. Liu, X. Xu, J. Luo, J. Wang, J. Gu, H. Wang and W. G. Zhu (2017). "Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer." Theranostics 7(5): 1346-1359.
9. Du, C., W. X. , F. D. , Y. P. , Y. Y. , J. Z. and J. G. (2017). "Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer." Int J Biol Markers 32(3): e267-e27.
10. Du, C., D. Huang, Y. Peng, Y. Yao, Y. Zhao, Y. Yang, H. Wang, L. Cao, W. G. Zhu and J. Gu (2017). "5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer." Cancer Lett 400: 183-193.